AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
30-07-2020
AstraZeneca partners on AI drug discovery collaboration
02-05-2019
Roland Magnusson / Shutterstock.com
AstraZeneca is planning to build a new global research and development centre in China.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AstraZeneca, China, research and development, medicine, artificial intelligence, China International Capital Corporation, big pharma
